Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Current Assets for 10 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 72.31% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 72.31% decrease, with the full-year FY2024 number at $13.7 million, down 25.23% from a year prior.
  • Current Assets was $5.2 million for Q3 2025 at Rein Therapeutics, down from $6.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $64.3 million in Q1 2021 to a low of $5.2 million in Q3 2025.
  • A 5-year average of $26.3 million and a median of $18.7 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 369.96% in 2021, then plummeted 72.31% in 2025.
  • Rein Therapeutics' Current Assets stood at $48.2 million in 2021, then plummeted by 54.6% to $21.9 million in 2022, then dropped by 16.49% to $18.3 million in 2023, then fell by 25.23% to $13.7 million in 2024, then plummeted by 62.11% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Current Assets are $5.2 million (Q3 2025), $6.6 million (Q2 2025), and $8.3 million (Q1 2025).